Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Even Pharma's Good Deeds Are Criticized
Forbes
Monday, May 6, 2013 - 9:16am
tags:
pharma industry, philanthropy
Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players
Motley Fool
Monday, May 6, 2013 - 9:12am
tags:
kidney cancer, ONYX Pharmaceuticals, Bayer, Nexavar, Roche, Avastin, Inlyta, Sutent, Pfizer, Votrient, GSK, Afinitor, Novartis, BMS-936558, Bristol-Myers Squibb, tivozanib, Aveo Oncology
Novartis Boost Seen in Fast Approvals as Protection Ends
Bloomberg
Monday, May 6, 2013 - 9:08am
tags:
drug approvals, Novartis, LDK378, lung cancer
Teva Pharmaceutical Industries Hits Estimates, But GAAP Results Lag Last Year's
Daily Finance
Sunday, May 5, 2013 - 11:09am
tags:
Teva, earnings
US FDA approves Raptor Pharma's Procysbi for treatment of nephropathic cystinosis
Pharmabiz
Sunday, May 5, 2013 - 11:07am
tags:
Raptor Pharmaceuticals, procysbi, nephropathic cystinosis
Pfizer’s Big Studies and Top Stories Affecting Dow 30 Healthcare This Week
Wall Street Cheat Street
Sunday, May 5, 2013 - 11:03am
tags:
Pfizer, Merck, JNJ
Bristol-Myers Has The Future Of Oncology Therapies
Seeking Alpha
Sunday, May 5, 2013 - 11:00am
tags:
Bristol-Myers Squibb, nivolumab, BMS-936558, non-small cell lung cancer, renal cell carcinoma, melanoma, Ono Pharmaceutical, tivozanib, Aveo Pharmaceuticals, elotuzumab
3 Promising Treatments for a Surprisingly Common Health Problem
Motley Fool
Sunday, May 5, 2013 - 10:54am
tags:
MK-7243, allergic rhinitis, allergies, Ragweed Allergy, Merck, MK-3461, ALK-Abello
AVEO: Here's Looking At You, FDA
Seeking Alpha
Sunday, May 5, 2013 - 10:48am
tags:
Aveo Pharmaceuticals, tivozanib, renal cell carcinoma
2 Biotechs To Avoid, 1 To Buy
Motley Fool
Sunday, May 5, 2013 - 10:46am
tags:
Aveo Pharmaceuticals, InterMune, Galena Biopharma
It's Pipeline That Matters Most
The Street
Saturday, May 4, 2013 - 11:05am
tags:
Merck, Allergan, JNJ
Neurocrine Biosciences CEO Discuses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha
Saturday, May 4, 2013 - 11:03am
tags:
Neurocrine Biosciences, earnings
FDA approves J&J sedation drug device
Reuters
Saturday, May 4, 2013 - 11:02am
tags:
JNJ, Sedasys, propofol
Why Investors Shouldn't Worry About Sanofi's Poor Quarter
Motley Fool
Saturday, May 4, 2013 - 10:50am
tags:
Sanofi, earnings
J&J Recalls Some Children’s Tylenol in South Korea
Bloomberg
Saturday, May 4, 2013 - 10:49am
tags:
JNJ, Tylenol, recalls
Merck's Cholesterol Pill Win Is Already Drawing Fire Comment Now Follow Comments
Forbes
Saturday, May 4, 2013 - 10:48am
tags:
Liptruzet, Merck, cholesterol
FDA OKs Bristol's HIV drug for younger patients
Yahoo/AP
Saturday, May 4, 2013 - 10:46am
tags:
Bristol-Myers Squibb, Sustiva, HIV
Rigel Pharmaceuticals Becomes Oversold (RIGL)
The Street
Saturday, May 4, 2013 - 10:45am
tags:
Rigel Pharmaceuticals
Repligen's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha
Saturday, May 4, 2013 - 10:33am
tags:
Repligen, earnings
Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential
Seeking Alpha
Saturday, May 4, 2013 - 10:32am
tags:
Vertex Pharmaceuticals, Pharmacyclics, Novartis, Celsion, Peregrine Pharmaceuticals, Prana, Navidea Biopharmaceuticals, Cardinal Health, ONYX Pharmaceuticals, Bayer, Sarepta, Hyperion Therapeutics, Amarin, Medivation, Astellas, JNJ, Trius, Sangamo BioSciences

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.